Intelicanna Ltd (INTL) - Net Assets
Based on the latest financial reports, Intelicanna Ltd (INTL) has net assets worth ILA8.45 Billion ILA (≈ $22.66 Million USD) as of September 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA63.16 Billion ≈ $169.34 Million USD) and total liabilities (ILA54.71 Billion ≈ $146.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Intelicanna Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA8.45 Billion |
| % of Total Assets | 13.38% |
| Annual Growth Rate | -13.54% |
| 5-Year Change | 8.07% |
| 10-Year Change | 76.06% |
| Growth Volatility | 29.75 |
Intelicanna Ltd - Net Assets Trend (2012–2022)
This chart illustrates how Intelicanna Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Intelicanna Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Intelicanna Ltd (2012–2022)
The table below shows the annual net assets of Intelicanna Ltd from 2012 to 2022. For live valuation and market cap data, see Intelicanna Ltd (INTL) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | ILA7.77 Billion ≈ $20.84 Million |
+14.68% |
| 2021-12-31 | ILA6.78 Billion ≈ $18.17 Million |
-3.75% |
| 2020-12-31 | ILA7.04 Billion ≈ $18.88 Million |
-12.78% |
| 2019-12-31 | ILA8.07 Billion ≈ $21.64 Million |
+12.24% |
| 2018-12-31 | ILA7.19 Billion ≈ $19.28 Million |
+4.68% |
| 2017-12-31 | ILA6.87 Billion ≈ $18.42 Million |
+14.65% |
| 2016-12-31 | ILA5.99 Billion ≈ $16.07 Million |
+22.01% |
| 2015-12-31 | ILA4.91 Billion ≈ $13.17 Million |
+0.33% |
| 2014-12-31 | ILA4.89 Billion ≈ $13.12 Million |
+10.88% |
| 2013-12-31 | ILA4.41 Billion ≈ $11.84 Million |
-86.74% |
| 2012-12-31 | ILA33.29 Billion ≈ $89.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Intelicanna Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA1.22 Billion | 15.99% |
| Common Stock | ILA346.57 Million | 4.55% |
| Other Components | ILA6.05 Billion | 79.46% |
| Total Equity | ILA7.62 Billion | 100.00% |
Intelicanna Ltd Competitors by Market Cap
The table below lists competitors of Intelicanna Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intrasense
PA:ALINS
|
$10.11 Million |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
$10.13 Million |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
$10.14 Million |
|
G.M. LEATHER S.P.A.
F:N78
|
$10.14 Million |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
$10.11 Million |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
$10.11 Million |
|
Scandinavian ChemoTech AB Series B
ST:CMOTEC-B
|
$10.09 Million |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
$10.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intelicanna Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 6,641,626,018 to 7,616,832,203, a change of 975,206,185 (14.7%).
- Net income of 1,217,377,686 contributed positively to equity growth.
- Dividend payments of 314,368,069 reduced retained earnings.
- Share repurchases of 21,967,786 reduced equity.
- Other factors increased equity by 94,164,354.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA1.22 Billion | +15.98% |
| Dividends Paid | ILA314.37 Million | -4.13% |
| Share Repurchases | ILA21.97 Million | -0.29% |
| Other Changes | ILA94.16 Million | +1.24% |
| Total Change | ILA- | 14.68% |
Book Value vs Market Value Analysis
This analysis compares Intelicanna Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.54x to 0.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA52.27 | ILA80.30 | x |
| 2013-12-31 | ILA53.12 | ILA80.30 | x |
| 2014-12-31 | ILA58.72 | ILA80.30 | x |
| 2015-12-31 | ILA59.47 | ILA80.30 | x |
| 2016-12-31 | ILA73.55 | ILA80.30 | x |
| 2017-12-31 | ILA84.29 | ILA80.30 | x |
| 2018-12-31 | ILA88.67 | ILA80.30 | x |
| 2019-12-31 | ILA99.38 | ILA80.30 | x |
| 2020-12-31 | ILA86.69 | ILA80.30 | x |
| 2021-12-31 | ILA83.36 | ILA80.30 | x |
| 2022-12-31 | ILA95.57 | ILA80.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intelicanna Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.98%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.94%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 8.17x
- Recent ROE (15.98%) is above the historical average (15.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 19.57% | 30.35% | 0.07x | 9.79x | ILA398.28 Million |
| 2013 | 13.00% | 19.89% | 0.07x | 9.64x | ILA127.02 Million |
| 2014 | 17.08% | 25.73% | 0.07x | 9.65x | ILA331.29 Million |
| 2015 | 19.17% | 30.17% | 0.07x | 9.64x | ILA434.38 Million |
| 2016 | 17.88% | 31.93% | 0.07x | 7.96x | ILA461.41 Million |
| 2017 | 18.81% | 35.70% | 0.07x | 7.84x | ILA591.57 Million |
| 2018 | 16.71% | 33.66% | 0.07x | 7.44x | ILA474.20 Million |
| 2019 | 16.26% | 33.74% | 0.07x | 7.16x | ILA495.43 Million |
| 2020 | 1.39% | 4.66% | 0.03x | 9.52x | ILA-594.27 Million |
| 2021 | 13.53% | 27.42% | 0.05x | 9.24x | ILA234.34 Million |
| 2022 | 15.98% | 29.94% | 0.07x | 8.17x | ILA455.69 Million |
Industry Comparison
This section compares Intelicanna Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,856,416,111
- Average return on equity (ROE) among peers: -135.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intelicanna Ltd (INTL) | ILA8.45 Billion | 19.57% | 6.47x | $10.11 Million |
| Canzon Israel Ltd (CNZN) | $9.28 Million | -40.91% | 0.07x | $1.81 Million |
| Intercure (INCR) | $521.48 Million | 8.59% | 0.84x | $36.88 Million |
| Kamada (KMDA) | $72.51 Million | -15.54% | 0.41x | $377.94 Million |
| Nextage Therapeutics Ltd (NXTG) | $1.45 Million | -1101.10% | 1.81x | $5.79 Million |
| Rekah Pharmaceutical Industry Ltd (REKA) | $162.08 Million | -1.26% | 1.77x | $34.76 Million |
| Seach Medical Group Ltd (SEMG) | $46.76 Million | -48.23% | 0.44x | $20.36 Million |
| Teva Pharmaceutical Industries Ltd (TEVA) | $15.79 Billion | -13.61% | 2.84x | $1.09 Billion |
| Together Startup Network Ltd (TGTR) | $323.00K | 0.00% | 0.31x | $10.46 Million |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $99.87 Million | -10.90% | 0.56x | $28.21 Million |
About Intelicanna Ltd
Intelicanna Ltd operates as pharmaceutical company in Israel. It grows, cultivates, produces, research, markets, and sells medical cannabis. The company was formerly known as Tefen Industrial Engineering & Management & Systems Analysis and changed its name to Intelicanna Ltd in March 2019. The company was founded in 1981 and is headquartered in Hod Hasharon, Israel.